How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)-Reference-Cited by-同舟云学术

How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)

Published:2020-11 Issue:11 Volume:26 Page:1464-1472
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Arendrup M.C.,Friberg N.,Mares M.,Kahlmeter G.,Meletiadis J.,Guinea J.,Arendrup M.C.,Meletiadis J.,Guinea J.,Friberg N.,Mares M.,Kahlmeter G.,Andersen C.T.,Arikan-Akdagli S.,Barchiesi F.,Chryssanthou E.,Hamal P.,Järv H.,Klimko N.,Kurzai O.,Lagrou K.,Lass-Flörl C.,Matos T.,Muehlethaler K.,Rogers T.R.,Velegraki A.,Arikan S.

Funder

Meso Scale Diagnostics

Gilead Sciences

Pfizer

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference37 articles.

1. Antifungal susceptibility profile of cryptic species of aspergillus;Alastruey-Izquierdo;Mycopathologia,2014

2. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome;Atkinson;Med Mycol,2008

3. Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots;Arendrup;Antimicrob Agents Chemother,2011